Literature DB >> 21800339

Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

Svetlana Marukian1, Linda Andrus, Timothy P Sheahan, Christopher T Jones, Edgar D Charles, Alexander Ploss, Charles M Rice, Lynn B Dustin.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) replication in primary liver cells is less robust than that in hepatoma cell lines, suggesting that innate antiviral mechanisms in primary cells may limit HCV replication or spread. Here we analyzed the expression of 47 genes associated with interferon (IFN) induction and signaling following HCV infection of primary human fetal liver cell (HFLC) cultures from 18 different donors. We report that cell culture-produced HCV (HCVcc) induced expression of Type III (λ) IFNs and of IFN-stimulated genes (ISGs). Little expression of Type I IFNs was detected. Levels of IFNλ and ISG induction varied among donors and, often, between adapted and nonadapted HCV chimeric constructs. Higher levels of viral replication were associated with greater induction of ISGs and of λ IFNs. Gene induction was dependent on HCV replication, as ultraviolet light-inactivated virus was not stimulatory and an antiviral drug, 2'-C-methyladenosine, reduced induction of λ IFNs and ISGs. The level of IFNλ protein induced was sufficient to inhibit HCVcc infection of naïve cultures.
CONCLUSION: Together, these results indicate that despite its reported abilities to blunt the induction of an IFN response, HCV infection is capable of inducing antiviral cytokines and pathways in primary liver cell cultures. Induction of ISGs and λ IFNs may limit the growth and spread of HCV in primary cell cultures and in the infected liver. HCV infection of HFLC may provide a useful model for the study of gene induction by HCV in vivo.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800339      PMCID: PMC3219820          DOI: 10.1002/hep.24580

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

1.  Chemokine antagonism in chronic hepatitis C virus infection.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.

Authors:  Laura Pedranzini; Tobias Dechow; Marjan Berishaj; Raymond Comenzo; Ping Zhou; Janeen Azare; William Bornmann; Jacqueline Bromberg
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

3.  IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Authors:  Thomas J Urban; Alexander J Thompson; Shelton S Bradrick; Jacques Fellay; Detlef Schuppan; Kenneth D Cronin; Linda Hong; Alexander McKenzie; Keyur Patel; Kevin V Shianna; John G McHutchison; David B Goldstein; Nezam Afdhal
Journal:  Hepatology       Date:  2010-10-07       Impact factor: 17.425

4.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Authors:  Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

Review 5.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

6.  Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures.

Authors:  Alexander Ploss; Salman R Khetani; Christopher T Jones; Andrew J Syder; Kartik Trehan; Valeriya A Gaysinskaya; Kathy Mu; Kimberly Ritola; Charles M Rice; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

7.  Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system.

Authors:  Christopher T Jones; Maria Teresa Catanese; Lok Man J Law; Salman R Khetani; Andrew J Syder; Alexander Ploss; Thomas S Oh; John W Schoggins; Margaret R MacDonald; Sangeeta N Bhatia; Charles M Rice
Journal:  Nat Biotechnol       Date:  2010-01-31       Impact factor: 54.908

8.  Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Authors:  Julia Diegelmann; Florian Beigel; Kathrin Zitzmann; Artur Kaul; Burkhard Göke; Christoph J Auernhammer; Ralf Bartenschlager; Helmut M Diepolder; Stephan Brand
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

9.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

10.  Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics.

Authors:  Deborah L Diamond; Andrew J Syder; Jon M Jacobs; Christina M Sorensen; Kathie-Anne Walters; Sean C Proll; Jason E McDermott; Marina A Gritsenko; Qibin Zhang; Rui Zhao; Thomas O Metz; David G Camp; Katrina M Waters; Richard D Smith; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more
  98 in total

1.  Modeling hepatitis C virus infection using human induced pluripotent stem cells.

Authors:  Robert E Schwartz; Kartik Trehan; Linda Andrus; Timothy P Sheahan; Alexander Ploss; Stephen A Duncan; Charles M Rice; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 3.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

4.  Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein.

Authors:  Hangfei Qi; Virginia Chu; Nicholas C Wu; Zugen Chen; Shawna Truong; Gurpreet Brar; Sheng-Yao Su; Yushen Du; Vaithilingaraja Arumugaswami; C Anders Olson; Shu-Hua Chen; Chung-Yen Lin; Ting-Ting Wu; Ren Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-03       Impact factor: 11.205

Review 5.  Interferon Lambda's New Role as Regulator of Neutrophil Function.

Authors:  Amariliz Rivera
Journal:  J Interferon Cytokine Res       Date:  2019-04-23       Impact factor: 2.607

Review 6.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 7.  Insights into antiviral innate immunity revealed by studying hepatitis C virus.

Authors:  Stacy M Horner
Journal:  Cytokine       Date:  2015-03-25       Impact factor: 3.861

8.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

9.  Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.

Authors:  Yizhong Wang; Jieliang Li; Xu Wang; Li Ye; Yu Zhou; Rebecca M Thomas; Wenzhe Ho
Journal:  Innate Immun       Date:  2013-03-25       Impact factor: 2.680

10.  MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1.

Authors:  Yongkui Li; Jiajia Xie; Xiupeng Xu; Jun Wang; Fang Ao; Yushun Wan; Ying Zhu
Journal:  Protein Cell       Date:  2012-11-12       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.